Free Trial
NASDAQ:RARE

Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis

Ultragenyx Pharmaceutical logo
$41.11 +1.69 (+4.29%)
As of 03:32 PM Eastern

About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE)

Key Stats

Today's Range
$39.70
$42.37
50-Day Range
$33.42
$39.61
52-Week Range
$29.59
$60.37
Volume
1.17 million shs
Average Volume
843,051 shs
Market Capitalization
$3.89 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.00
Consensus Rating
Moderate Buy

Company Overview

Ultragenyx Pharmaceutical Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

RARE MarketRank™: 

Ultragenyx Pharmaceutical scored higher than 81% of companies evaluated by MarketBeat, and ranked 189th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Ultragenyx Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 13 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Ultragenyx Pharmaceutical has only been the subject of 3 research reports in the past 90 days.

  • Read more about Ultragenyx Pharmaceutical's stock forecast and price target.
  • Earnings Growth

    Earnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($5.18) to ($3.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ultragenyx Pharmaceutical is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ultragenyx Pharmaceutical is -7.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ultragenyx Pharmaceutical has a P/B Ratio of 15.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Ultragenyx Pharmaceutical's valuation and earnings.
  • Percentage of Shares Shorted

    6.81% of the float of Ultragenyx Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Ultragenyx Pharmaceutical has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Ultragenyx Pharmaceutical does not currently pay a dividend.

  • Dividend Growth

    Ultragenyx Pharmaceutical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.81% of the float of Ultragenyx Pharmaceutical has been sold short.
  • Short Interest Ratio / Days to Cover

    Ultragenyx Pharmaceutical has a short interest ratio ("days to cover") of 6.
  • Change versus previous month

    Short interest in Ultragenyx Pharmaceutical has recently increased by 9.55%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Ultragenyx Pharmaceutical has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Ultragenyx Pharmaceutical this week, compared to 8 articles on an average week.
  • Search Interest

    6 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $118,824.00 in company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of Ultragenyx Pharmaceutical is held by insiders.

  • Percentage Held by Institutions

    97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Ultragenyx Pharmaceutical's insider trading history.
Receive RARE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

RARE Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
See More Headlines

RARE Stock Analysis - Frequently Asked Questions

Ultragenyx Pharmaceutical's stock was trading at $42.07 at the start of the year. Since then, RARE shares have decreased by 1.0% and is now trading at $41.65.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued its quarterly earnings data on Tuesday, May, 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by $0.03. The company's revenue for the quarter was up 28.0% on a year-over-year basis.
Read the conference call transcript
.

Top institutional investors of Ultragenyx Pharmaceutical include Woodstock Corp (0.01%) and Parallel Advisors LLC. Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, John Richard Pinion, Howard Horn, Dennis Karl Huang, Eric Crombez, Mardi Dier, Karah Herdman Parschauer, Erik Harris, Theodore Alan Huizenga, Camille L Bedrosian, Corazon (Corsee) D Sanders and Matthew K Fust.
View institutional ownership trends
.

Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/06/2025
Today
7/09/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RARE
CIK
1515673
Employees
1,294
Year Founded
2010

Price Target and Rating

High Price Target
$136.00
Low Price Target
$48.00
Potential Upside/Downside
+108.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.93
Research Coverage
14 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$569.18 million
Pretax Margin
-92.62%

Debt

Sales & Book Value

Annual Sales
$560.23 million
Price / Cash Flow
N/A
Book Value
$2.76 per share
Price / Book
15.09

Miscellaneous

Free Float
89,342,000
Market Cap
$3.94 billion
Optionable
Optionable
Beta
0.26

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:RARE) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners